Sandbox g23

Jump to navigation Jump to search

Encephalitis

  • Empiric antimicrobial therapy[1]
  • Preferred regimen: Acyclovir 10 mg/kg IV q8h for 14–21 days
Note (1): Acyclovir should be initiated in all patients with sus- pected encephalitis, pending results of diagnostic studies.
Note (2): Other empirical antimicrobial agents should be initiated on the basis of specific epidemiologic or clinical clues.
  • Specific considerations
  • Pathogen-directed antimicrobial therapy[2]
  • Viruses
  • Preferred regimen: supportive
prophylactic antiviral therapy after bite or scratch
established disease
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • HSV-1 and HSV-2
  • Preferred regimen: Acyclovir 10 mg/kg IV q8h for 14–21 days
  • Preferred regimen (neonates): Acyclovir 20 mg/kg IV q8h for 21 days


  • Preferred regimen: supportive
  • Preferred regimen: Reversal or control of immunosuppression AND HAART in patients with AIDS
  • Preferred regimen: supportive
life-threatening disease
SSPE
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Preferred regimen: supportive AND Intraventricular γ-globulin (for chronic and/or severe disease)
  • Preferred regimen: supportive
  • Preferred regimen: supportive
postxposure prophylaxis
  • Preferred regimen: rabies immunoglobulin AND vaccine
after onset of disease
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • St. Louis encephalitis virus
  • Preferred regimen: supportive
  • Alternative regimen: IFN-a-2b
  • Tickborne encephalitis virus
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Bacteria
  • Ehrlichia chaffeensis (human monocytotrophic ehrlichiosis)
with meningitis
without meningitis
  • Fungi
  • Preferred regimen: Amphotericin B deoxycholate AND flucytosine for 2 weeks, followed by fluconazole for 8 weeks ORv Lipid formulation of amphotericin B AND flucytosine for 2 weeks, followed by fluconazole for 8 weeks OR Amphotericin B AND flucytosine for 6–10 weeks
  • Preferred regimen: Liposomal amphotericin B for 4–6 weeks, followed by itraconazole for at least 1 year and until resolution of CSF abnormalities
  • Protozoa
  • Preferred regimen: Quinine OR quinidine OR artesunate OR artemether
  • Alternative regimen: Atovaquone OR proguanil OR Exchange transfusion (less than 10% parasitemia or cere- bral malaria)
  • Helminths
  • Prion
  • Preferred regimen: supportive
  1. Tunkel, Allan R.; Glaser, Carol A.; Bloch, Karen C.; Sejvar, James J.; Marra, Christina M.; Roos, Karen L.; Hartman, Barry J.; Kaplan, Sheldon L.; Scheld, W. Michael; Whitley, Richard J.; Infectious Diseases Society of America (2008-08-01). "The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 47 (3): 303–327. doi:10.1086/589747. ISSN 1537-6591. PMID 18582201.
  2. Tunkel, Allan R.; Glaser, Carol A.; Bloch, Karen C.; Sejvar, James J.; Marra, Christina M.; Roos, Karen L.; Hartman, Barry J.; Kaplan, Sheldon L.; Scheld, W. Michael; Whitley, Richard J.; Infectious Diseases Society of America (2008-08-01). "The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 47 (3): 303–327. doi:10.1086/589747. ISSN 1537-6591. PMID 18582201.